Last reviewed · How we verify
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)
The purpose of this study is to evaluate the change in serum potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - \< 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too much potassium in the blood). Another purpose of the study is to evaluate the safety and tolerability of patiromer in children 2 - \< 18 years of age with CKD and hyperkalemia.
Details
| Lead sponsor | Vifor Pharma, Inc. |
|---|---|
| Phase | PHASE2 |
| Status | TERMINATED |
| Enrolment | 23 |
| Start date | Fri Jul 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Apr 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hyperkalemia
Interventions
- Patiromer
- Patiromer
- Patiromer
Countries
Georgia, Ukraine, Germany, Poland, Canada, Bulgaria, United States